Back

Insulin Resistance's Impact on Cognition in Middle Aged Adults from the PREVENT cohort: Interactive Effects with Depression

Bauermeister, S.; Reid, G.; Yehuda, M. B.; Howgego, G.; Ritchie, K.; Watermeyer, T.; Gregory, S.; Muniz, G. T.; Koychev, I.

2023-02-02 psychiatry and clinical psychology
10.1101/2023.01.31.23285252 medRxiv
Show abstract

BackgroundAlzheimers disease, type 2 diabetes mellitus, and depression are significant challenges facing public health. Research has demonstrated common comorbidities amongst these three conditions, typically focusing on two of them at a time. ObjectivesThe goal of this study, however, was to assess the interrelationships between the three conditions, focusing on mid-life risk before the emergence of dementia caused by Alzheimers Disease. MethodsIn the current study, we used data from 665 participants from the prospective cohort study, PREVENT. FindingsUsing structural equation modelling, we showed that (i) insulin resistance predicts executive dysfunction in older but not younger adults in midlife, that (ii) insulin resistance predicts self-reported depression in both older and younger middle-aged adults, and that (iii) depression predicts deficits in visuospatial memory in older but not younger adults in midlife. ConclusionsTogether, we demonstrate the interrelations between three common non-communicable diseases in middle-aged adults. Clinical ImplicationsWe emphasise the need for combined interventions and the utilisation of resources to help adults in midlife to modify risk factors for cognitive impairment, such as depression and diabetes. FundingThe PREVENT study was funded by the Alzheimers Society (grant numbers 178 and 264), the Alzheimers Association (grant number TriBEKa-17-519007) and philanthropic donations. GR acknowledges funding for this work for his research programme funded by the Medical Research council (Dementias Platform UK) and Five Lives Ltd. IK declares funding for this project through Medical Research Council (Dementias Platform UK), NIHR Oxford Health Biomedical Research Centre and NIHR personal awards. SG acknowledges funding for salary from the Medical Research Council Nutrition Research Partnership Collaboration Award (MR/T001852/1). Key MessagesO_ST_ABSWhat is already known on this topicC_ST_ABSMood disorders and metabolic diseases are known to be frequently comorbid. Furthermore, both conditions are known to be associated with cognitive impairment and cognitive decline. There has been some evidence that the risk of cognitive impairment associated with diabetes and depression is most notable in midlife. However, studies focusing on this period of life have been sparse and most research has modelled bivariate correlations amongst cognitive impairment, depression, and diabetes. As such, this study was conducted in order to model the interrelations between the three conditions in a large cohort, whilst focusing on midlife as depression and diabetes in this period are thought to carry higher risk for cognitive impairment. What this study addsWhilst insulin resistance, as a core feature of diabetes, was related to depression across all stages of midlife, the relationship with cognitive functioning was more complex. In the current study, we found that the stage of midlife in which middle-aged adults find themselves moderates the relationship between insulin resistance and cognition and depression and cognition. That is, only in older middle aged adults does insulin resistance predict impaired cognition (i.e., executive function) and does depression predict impaired cognition (i.e., visuospatial memory). How this study might affect research, practice or policyClinicians should be mindful of the impact of comorbidities between cognitive impairment, metabolic diseases, such as diabetes, and mood disorders, such as depression in midlife. Given the risk of intractable dementia in individuals with cognitive impairment, available resources for intervening in modifiable risk factors, such as depression and diabetes, should be considered for adults in the middle period of life.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Journal of Alzheimer's Disease
43 papers in training set
Top 0.1%
12.9%
2
Alzheimer's & Dementia: Translational Research & Clinical Interventions
16 papers in training set
Top 0.1%
9.3%
3
BMJ Open
554 papers in training set
Top 3%
7.3%
4
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
38 papers in training set
Top 0.2%
6.9%
5
Age and Ageing
27 papers in training set
Top 0.1%
6.5%
6
PLOS ONE
4510 papers in training set
Top 31%
4.9%
7
Journal of the American Medical Directors Association
13 papers in training set
Top 0.1%
4.0%
50% of probability mass above
8
Journal of Neurology, Neurosurgery & Psychiatry
29 papers in training set
Top 0.3%
3.7%
9
BMC Psychiatry
22 papers in training set
Top 0.2%
2.6%
10
Alzheimer's & Dementia
143 papers in training set
Top 2%
2.5%
11
Brain and Behavior
37 papers in training set
Top 0.3%
2.1%
12
The British Journal of Psychiatry
21 papers in training set
Top 0.4%
2.1%
13
Journal of Affective Disorders
81 papers in training set
Top 0.8%
2.1%
14
Frontiers in Aging Neuroscience
67 papers in training set
Top 2%
1.7%
15
Brain Communications
147 papers in training set
Top 2%
1.7%
16
Acta Neuropsychiatrica
12 papers in training set
Top 0.4%
1.7%
17
Brain, Behavior, and Immunity
105 papers in training set
Top 1%
1.7%
18
European Psychiatry
10 papers in training set
Top 0.5%
1.2%
19
Alzheimer's Research & Therapy
52 papers in training set
Top 1%
1.2%
20
Neurology
44 papers in training set
Top 1%
1.0%
21
EClinicalMedicine
21 papers in training set
Top 0.6%
1.0%
22
Scientific Reports
3102 papers in training set
Top 70%
0.9%
23
Social Science & Medicine
15 papers in training set
Top 0.8%
0.9%
24
International Journal of Epidemiology
74 papers in training set
Top 2%
0.8%
25
Translational Psychiatry
219 papers in training set
Top 4%
0.8%
26
Psychiatry Research
35 papers in training set
Top 1%
0.8%
27
NeuroImage: Clinical
132 papers in training set
Top 4%
0.8%
28
Journal of Psychosomatic Research
11 papers in training set
Top 0.4%
0.7%
29
Journal of Alzheimer’s Disease
39 papers in training set
Top 1%
0.5%
30
PLOS Medicine
98 papers in training set
Top 6%
0.5%